Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, from the UK’s Medical and Healthcare products Regulatory Agency (MHRA) and approval to open its Investigational New Drug (IND) application by the FDA in the US.
SolasCure’s mission is to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.
Wellington House East Road Cambridge
Post Code: CB1 1BH
Country: United Kingdom
Membership Type: Corporate 6-20